Orphan Drug Fairness Act

Fact Sheet API

Bill Number

HR 3618

Introduced

Sep 25, 2015

Latest Action

Referred to the Subcommittee on Health.

Sponsor

Cosponsors

Topics

Drug safety, medical device, and laboratory regulation Drug therapy Health Income tax credits Prescription drugs User charges and fees

Full Text

View Full Bill Text

Votes

Summary

Orphan Drug Fairness Act

This bill amends the Patient Protection and Affordable Care Act (PPACA) to exclude sales of any drug or biological product approved by the Food and Drug Administration solely for rare diseases or conditions (orphan drug) from the calculation of the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million.

This Act is effective as if included in PPACA.

Actions

Oct 2, 2015

Referred to the Subcommittee on Health.
Sep 25, 2015

Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sep 25, 2015

Introduced in House

Amendments

Related Bills